A study of the DurAVR heart valve for aortic stenosis
Part of Heart & circulation clinical trials.
This trial tests a new heart valve called DurAVR for people with severe aortic stenosis (a narrowed aortic valve) who need a valve replacement. It compares the new valve to standard valves to see if it is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe aortic stenosis that needs treatment with a valve replacement procedure called TAVR.
- Your heart team agrees that TAVR is right for you.
- You have not had a heart attack in the last 30 days.
- You do not have another heart valve problem that is severe or a mechanical valve already in place.
- You do not have active infection inside your heart or bleeding in your stomach in the last 3 months.
- Your doctor expects you to live more than 12 months after the procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new device called the RENATUS® Transcatheter Aortic Valve System for people with severe aortic stenosis. It is designed to replace the narrowed valve without open-heart surgery, and aims to see if it is safe and effective for patients with various surgical risk levels.
This study checks whether an “investigational” transcatheter aortic valve is safe and works well for people with severe, calcified aortic stenosis (a stiff, narrowed heart valve). It may help improve valve function and symptoms, but you must meet specific heart, scan, and health-status requirements.
This trial studies whether a new through-the-blood-vessel heart valve (TAVR) is safe and works well for people with severe aortic stenosis who are too risky for traditional surgery. If you qualify, you would be closely followed to check your symptoms and valve function over time.
This study compares regular monitoring (“clinical surveillance”) versus replacing the aortic valve using a minimally invasive procedure called TAVR for people with moderate aortic stenosis. It aims to see which approach better reduces symptoms or heart damage over time.
This study follows patients with severe aortic stenosis who get a new heart valve (the SAPIEN 3 Ultra RESILIA) through a less invasive procedure (TAVR). Researchers want to see how well this valve works over time using special heart ultrasound tests.
This trial tests a new version of a heart valve (SAPIEN X4) placed without open-heart surgery. It's for people with severe aortic stenosis who have symptoms like shortness of breath or chest pain.
Hear when a new Severe Aortic Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.